Exploratory randomized phase II trial for optimizing treatment dosage and duration of adjuvant S-1 plus oxaliplatin in patients with stage III colon cancer: YCOG1402 (SOAP trial).
Yusuke SuwaJun WatanabeHirokazu SuwaMayumi OzawaMasashi MomiyamaAtsushi IshibeKotaro NagamineShigeru YamagishiMitsuyoshi OtaTadao FukushimaHitoshi SekidoYusuke SaigusaItraru EndoPublished in: Annals of gastroenterological surgery (2023)
The 3-year DFS was not significantly superior to null hypothesis in both 3 months and 6 months arms for the stage III colon cancer. Primary endpoint was not achieved. The SOX regimen was not feasible in long-term outcomes.